Zynerba Pharmaceuticals I... (ZYNE)
NASDAQ: ZYNE
· Real-Time Price · USD
1.30
0.03 (2.36%)
At close: Oct 10, 2023, 10:00 PM
Zynerba Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 35.97M | 44.4M | 50.64M | 55.93M | 62.49M | 69.7M | 67.81M | 75.64M | 85.78M | 93.13M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 567.65K | 309.19K | n/a | 751.82K | 560.75K | 264.21K | n/a | 868.08K | 552.92K | 338.81K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | 1.39M | 1.43M | n/a | 2.98M | 1.04M | 1.69M | n/a | 3.24M | 1.2M | 1.79M |
Other Current Assets | 3.33M | 3.18M | 4.13M | 4.87M | 3.18M | 3.53M | 12.41M | 12.42M | 10.67M | 14.07M |
Total Current Assets | 39.29M | 47.58M | 54.78M | 60.8M | 65.67M | 73.23M | 80.22M | 88.06M | 96.46M | 107.2M |
Property-Plant & Equipment | 613.94K | 751.1K | 745.79K | 814.07K | 774.51K | 885.75K | 951.65K | 1.07M | 1.19M | 1.27M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 1.18M | 1.06M | 745.79K | 1.57M | 1.34M | 1.15M | 951.65K | 1.94M | 1.74M | 1.61M |
Total Assets | 40.48M | 48.64M | 55.52M | 62.37M | 67.01M | 74.38M | 81.17M | 90M | 98.2M | 108.81M |
Account Payables | 2.48M | 2.14M | 1.94M | 1.62M | 1.67M | 1.6M | 1.8M | 2.64M | 1.82M | 1.68M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 217.88K | 216.38K | 214.9K | 213.43K | 211.97K | 210.51K | 209.07K | 207.63K | 206.21K | 209.32K |
Other Current Liabilities | 8.76M | 7.25M | 7.01M | 7.6M | 7.64M | 7.1M | 7.9M | 8.05M | 8M | 10.68M |
Total Current Liabilities | 11.46M | 9.61M | 9.17M | 9.43M | 9.53M | 8.92M | 9.9M | 10.9M | 10.03M | 12.57M |
Long-Term Debt | n/a | 59.97K | 119.52K | 178.67K | 237.41K | 295.75K | 353.69K | 411.24K | 468.38K | 525.14K |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | n/a | 59.97K | 119.52K | 178.67K | 237.41K | 295.75K | 353.69K | 411.24K | 468.38K | 525.14K |
Total Liabilities | 11.46M | 9.67M | 9.29M | 9.61M | 9.77M | 9.21M | 10.26M | 11.31M | 10.5M | 13.09M |
Total Debt | 217.88K | 276.35K | 334.43K | 392.1K | 449.38K | 506.27K | 562.76K | 618.87K | 674.6K | 734.47K |
Common Stock | 53.94K | 53.5K | 47.9K | 47.06K | 43.94K | 43.32K | 41.22K | 41.28K | 41.25K | 41.25K |
Retained Earnings | -295.41M | -284.63M | -274.52M | -266.5M | -257.83M | -247.97M | -239.48M | -230.67M | -220.08M | -210.13M |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shareholders Equity | 29.02M | 38.97M | 46.23M | 52.76M | 57.24M | 65.17M | 70.91M | 78.69M | 87.7M | 95.71M |
Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |